Cobalamin Analogs (i.e., Compounds Wherein The Benzimidazole Ring System Has Been Replaced By Another Organic Ring Structure, Or Compounds Wherein Cobalt Has Been Removed Or Replaced By Another Metal, Or Is Substituted By A Group Other Than -oh Or -cn) Patents (Class 536/26.44)
-
Publication number: 20110076598Abstract: The invention provides metal-containing corrin compounds as catalysts for oxygen reduction in electrochemical devices, such as in fuel cells. The catalysts provide more efficient reduction at lower cost than conventional noble metal catalyst. Methods for preparing the catalysts are also provided.Type: ApplicationFiled: September 30, 2009Publication date: March 31, 2011Applicant: ACADEMIA SINICAInventors: Kuei-Hsien CHEN, Chen-Hao WANG, Hsin-Cheng HSU, Sun-Tang CHANG, Li-Chyong CHEN
-
Patent number: 7910594Abstract: This invention relates to vitamin-mitomycin conjugates, to a method of using the conjugates to selectively eliminate a population of pathogenic cells in a host animal harboring the pathogenic cells, and to a method of preparation of the conjugates. The conjugate is of the general formula B-L-X wherein the group B is a vitamin, or an analog or a derivative thereof, that binds to a surface accessible vitamin receptor that is uniquely expressed, overexpressed, or preferentially expressed by a population of pathogenic cells, wherein the group L comprises a cleavable linker, and wherein the group X comprises a mitomycin compound, or an analog or a derivative thereof. An additional therapeutic agent, such as a chemotherapeutic agent, can be administered in combination with the conjugate.Type: GrantFiled: May 13, 2003Date of Patent: March 22, 2011Assignee: Endocyte, Inc.Inventors: Iontcho Radoslavov Vlahov, Christopher P. Leamon
-
Patent number: 7692002Abstract: The present invention relates to a metal complex of the general formula M(L)n, wherein each L is independently selected and represents a ligand and at least one L is vitamin B12 (cyanocobalamin) or a derivative thereof bound through the nitrogen atom of its cyanide group to M, which is an element selected from the transition metals, thus, forming a M-NC-[Co] moiety with [Co] representing vitamin B12 without cyanide and wherein n is 1, 2, 3, 4, 5 or 6. The complex can be prepared by mixing a precursor molecule with vitamin B12. The metal complexes can be used for radiodiagnostics, chemotherapy and radionuclide therapy.Type: GrantFiled: January 10, 2005Date of Patent: April 6, 2010Assignee: University of ZurichInventors: Roger Alberto, Susanne Barbara Kunze, Hector Knight Castro, Stefan Mundwiler
-
Patent number: 7531162Abstract: An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed.Type: GrantFiled: February 13, 2006Date of Patent: May 12, 2009Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus P. C. Hogenkamp
-
Patent number: 7468432Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.Type: GrantFiled: February 12, 2004Date of Patent: December 23, 2008Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus P. C. Hogenkamp
-
Patent number: 6905884Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.Type: GrantFiled: June 15, 2004Date of Patent: June 14, 2005Assignee: University of Utah Research FoundationInventors: Charles B. Grissom, Frederick G. West, James McGreevy, Joel S. Bentz, Michelle J. Cannon
-
Publication number: 20040224921Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.Type: ApplicationFiled: June 15, 2004Publication date: November 11, 2004Applicant: University of Utah Research FoundationInventors: Charles B. Grissom, Frederick G. West, James McGreevy, Joel S. Bentz, Michelle J. Cannon
-
Patent number: 6806363Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.Type: GrantFiled: October 16, 2000Date of Patent: October 19, 2004Assignees: Mayo Foundation for Medical Education & Research, Minnesota, Regents of the UniversityInventors: Douglas A. Collins, Henricus P. C. Hogenkamp
-
Patent number: 6797521Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.Type: GrantFiled: March 15, 2002Date of Patent: September 28, 2004Assignee: University of Utah Research FoundationInventors: Charles B. Grissom, Frederick G. West, James McGreevy, Joel S. Bentz, Michelle J. Cannon
-
Publication number: 20040132687Abstract: The present invention provides a novel industrially excellent and ecological process for producing methylcobalamin which is useful as a medicament etc. More specifically, it provides a process for producing methylcobalamin by reducing cyanocobalamin or hydroxocobalamin in the presence of a reducing agent, and then methylating the reductant by adding a water-soluble methylating agent.Type: ApplicationFiled: October 30, 2003Publication date: July 8, 2004Inventors: Yoshihiko Hisatake, Takuo Tanaka, Tomio Tsurugi, Hiroshi Kuroda
-
Patent number: 6613305Abstract: A compound useful for in vivo imaging of organs and tumors is provided of formula: wherein is a cobalamin, is derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3.Type: GrantFiled: July 26, 2000Date of Patent: September 2, 2003Assignees: Mayo Foundation for Medical Education & Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus Petrus Hogenkamp
-
Publication number: 20020192683Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.Type: ApplicationFiled: March 15, 2002Publication date: December 19, 2002Inventors: Charles B. Grissom, Frederick G. West, James McGreevy, Joel S. Bentz, Michelle J. Cannon
-
Publication number: 20020183511Abstract: The present invention provides an industrially excellent and novel process for producing methylcobalamin useful as medicines. Namely, it provides a process for producing methylcobalamin, which comprises the step of methylating cyanocobalamin or hydroxocobalamin in the presence of a reducing agent and a water-soluble methylating agent.Type: ApplicationFiled: May 23, 2002Publication date: December 5, 2002Inventors: Yoshihiko Hisatake, Hiroshi Kuroda
-
Publication number: 20020042394Abstract: The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a microbial infection.Type: ApplicationFiled: May 31, 2001Publication date: April 11, 2002Inventors: Henricus P.C. Hogenkamp, Douglas A. Collins
-
Patent number: 6262253Abstract: The invention describes complexes between VB12 analogues and either GCSF or EPO that retain both significant affinity for intrinsic factor (IF) in the VB12 portion of the complex and significant bioactivity of the GCSF or EPO portion of the complex. The invention also concerns a process for the synthesis of these complexes. This is achieved at least in part, by using a spacer compound, which is linked covalantly between the VB12 portion and the GCSF or EPO.Type: GrantFiled: February 5, 1999Date of Patent: July 17, 2001Assignee: Biotech Australia Pty LimitedInventors: Gregory John Russell-Jones, Steven William Westwood
-
Patent number: 6211355Abstract: A compound useful for in vivo imaging of organs and tumors is provided of formula: wherein is a cobalamin, is derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3.Type: GrantFiled: February 8, 2000Date of Patent: April 3, 2001Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus Petrus Hogenkamp